LDS/Medical Tests/GlycoMark

GlycoMark

GlycoMark is a new advanced test used to monitor glycemia (high blood sugar) in diabetes patients, especially in patients with unstable or variable glucose metabolism. Currently the most commonly used markers for assessment of glycemia include self-monitored blood glucose methods and assays for HbA1c and fructosamine. However, these markers, and especially HbA1c, are not rapidly changing markers that might indicate rapid changes in diabetes patients. Thus the need for a marker that responds rapidly and significantly to changes in glycemia, and which is metabolically more stable and less biologically variable, led to the discovery of the 1,5-Anhydroglucitol (1,5AG) marker. 1,5AG is a major circulating polyol released and excreted with glucose and can be easily measured as a marker to monitor changes in glycemia, and as a marker in management of patients with diabetes. It is 99.9% reabsorbed by the renal tubule, and reabsorption is competitively inhibited by glucose. Therefore, lower blood levels of 1,5-AG are indicative of hyperglycemia. Since 1,5-AG levels change more rapidly than HbA1c levels and reflect glycemia, it is a better marker to monitor glycemia in patients with unstable diabetes. A proprietary assay (GlycoMark) developed by Quest Diagnostics has been under evaluation in clinical trials in the U.S. and has recently been cleared for marketing by the FDA as a tool for intermediate-term monitoring of glycemia.

  • Management of patients with type 1 or 2 diabetes mellitus
  • This test is used for intermediate-term monitoring of glycemic control in patients with diabetes
  • Good marker for monitoring patients with unstable glucose metabolism such as those with unstable diabetes

Increased in:

  • In patients with moderate- to well-controlled diabetes (HbA1c < 6.0%)
  • Increasing levels reflect a positive short- to intermediate-term response when monitoring changes in diet or medication
  • Increased levels are associated with intravenous hyperalimentation and some Chinese medicines (e.g., Polygala tenuifolia and Senega syrup)

Decreased in:

  • In patients with poorly controlled diabetes, in vivo levels of 1,5AG may be depleted; thus, in this group 1,5AG measurements may not accurately reflect therapeutic response
  • Low levels of 1,5AG primarily reflect postprandial hyperglycemia, and measures aimed at decreasing the postprandial blood glucose level are indicated
  • Low levels are also associated with pregnancy, kidney disease, advanced cirrhosis, prolonged inability to intake food orally, and steroid therapy

Adults
Males 7.3-36.6.0 µg/mL
Females 7.5-28.4 µg/mL

Children 2-17 years:
Males 15.0-38.0 µg/mL
Females 11.2-35.7 µg/mL
 

 

1,5AG is measured colorimetrically following enzymatic release of hydrogen peroxide.

Serum (SST) or Plasma EDTA (Lavender). 

Stability

  • Ambient: 7 days
  • Refrigerated: 7 days
  • Frozen: 28 days
Glucose, Insulin, C-peptide, Insulin antibodies, Hemoglobin A1C, Islet cell antibodies, Comprehensive metabolic panel, Fructosamine.

1-3 days. 

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login